Researchers at the University of California, San Francisco (UCSF), are developing an implantable artificial kidney that can closely replicate the functions of real kidneys. The Kidney Project is raising money to complete preclinical studies of the device modules and to build full-scale prototypes for the first round of human studies. Initial clinical trials on the individual modules are expected to begin early next year. Testing of a working prototype of the bioartificial kidney is slated for 2020.
More than 40% of sleep apnea sufferers refuse to wear CPAP machines, because of noise, mask irritation and claustrophobia. Neuromodulation is an alternative!
An implant that is inserted during minimally-invasive surgery stimulates certain airways and help with breathing. According to Cleveland Clinic's Sleep Disorder Center, the system has not caused any serious complications in clinical testing
According to a recent Washington Examiner article, one third of the US population suffers from chronic pain. Per the same article, 90 percent of doctors practicing medicine in America today do not know how to treat chronic pain. In 2015, 33 thousand lives were lost to opioid-related causes, and 45 percent of those deaths involved a prescription.
Not surprisingly, recently President Trump has declared Opioid Epidemic a Public Health Crisis.
Electronic neurostimulators with little or no side effects can be the answer to many problem, yet, surprisingly less than 100 thousand chronic pain sufferers can receive Spinal Cord Stimulation (SCS) per year.
New advanced neurostimulation devices, including the ones that can be fully programmed for customized personal care can help combat the opioid crises quickly and affordably. Further, programmable neurostimulators promise to accelerate medical research in areas of other neurological disorders.
The bottom line is, with the fully programmable neurostimulators, the solution to opioid crisis and new advanced therapies for many neurological disorders are much closer than we think.
A randomized controlled trial (Click here to access the source) has found excellent pain relief and no clinical difference among spinal cord stimulation frequencies from 1kHz to 10kHz, including 1kHz, 4kHz, 7Khz, and 10Khz.
Since 1kHz stimulation provides similar pain relief using significantly less energy than higher frequencies, devices with higher battery-charge longevity are possible and should be better alternatives to the 10kHz HF10 therapy.
A recent study suggests that executive functions can be rapidly up- or down-regulated by modulating theta phase coupling of distant frontal cortical areas and can contribute to the development of tools for potentially normalizing executive dysfunction in patient populations.
About 75 percent of people with MS (Multiple Sclerosis) report fatigue among their most disabling disease symptoms.
Medications, such as those that treat narcolepsy, behavior-based therapies and even exercise programs are often prescribed but benefits have been found to be unreliable.
When compared to patients who were enrolled in a placebo arm of a recent study those that received transcranial direct current stimulation (tDCS) were found to have about a six-point drop on a 32-point scale measuring fatigue severity, according to the findings recently published online in the Multiple Sclerosis Journal.
The exact mechanism behind tDCS is unclear and requires more research. It is thought to change the brain's cortical excitability by making it easier for neurons to fire, thereby improving connections and expediting learning that takes place during rehabilitation.
In a recent trial, a vegetative-state patient responds to Vagal Nerve Stimulation (VNS) in an experimental therapy.
However, article suggests that VNS may not work as effectively in patients with different patterns of brain damage.
Perhaps a fully-programmable electrical pulse generator platform is ideal for this application, since it is not practical to develop custom pulse generators for every patient using an ASIC-based platform.
New treatment options are being studied and proposed but much work is required to understand how these technologies are best matched with specific patients and pain syndromes.
A recent article delves into the details of this topic. The article concludes with a statement that "the field will undoubtedly continue to grow and force reconsideration of current treatment paradigms.".
This implies that new research on new paradigms require new devices. Flexible, programmable, indication-agnostic devices can play a key role in accelerating medical research, given the fact that developing a new purpose-built device requires a dedicated development team and heavy investment in time, and money.
A programmable device can enable new research overnight.
A new pilot trial is aiming to determine the feasibility, safety and perceived patient response to a combined transcranial direct current stimulation (tDCS) and sensorimotor retraining intervention in chronic lower back pain and provide data to support a sample size calculation for a fully powered trial should trends of effectiveness be present.
Lone Star NeuroMODULATION
LSN is targeting unmet clinical needs by creating disruptive device platforms that offer promising solutions for lowering costs, realizing higher returns and effectively addressing more therapeutic indications if adopted for medical applications.